M Ventures Strengthens Biotechnology Investment Team With Senior Hire and Promotion

According to a recent LinkedIn post from M Ventures, the firm is strengthening its biotechnology investment team with both an external hire and an internal promotion. The post highlights the appointment of Emma Johnson as Senior Principal and the promotion of Charlotte Kremers to Principal, both based in the Amsterdam office.

The LinkedIn post notes that Johnson brings eight years of venture capital experience, including four years leading direct healthcare and life sciences investments at the British Business Bank. Her track record in Series A to Series C financings and prior co-investments with M Ventures in Nucleome Therapeutics and NRG Therapeutics suggests continuity and potential depth in later-stage deal execution.

The post also describes Johnson’s background in cognitive neuroscience and her prior board roles across companies from discovery through approval stages. For investors, this profile may signal an emphasis on scientifically rigorous evaluation and active portfolio governance in the firm’s biotech strategy.

According to the same LinkedIn update, Kremers’ promotion reflects a rapid progression from Fellow to Principal since joining in 2022. The post indicates that she has been involved with six portfolio companies, holds multiple board or observer seats, and has co-led five new investments, including in NRG and Trimtech.

Her academic specialization in neuroscience and experience in biotech strategy consulting and fundraising may support M Ventures’ ability to source and structure early-stage opportunities in complex therapeutic areas. Overall, the team changes suggested in the post point to an incremental build-out of investment capacity in biotechnology, which could influence the firm’s deal flow, portfolio support, and long-term value creation in the life sciences sector.